If it’s big enough to buy ONCS and/or to distribute ONCS in Asia than that is big enough for my purposes. The fact that it is not as big as Merck is immaterial. Although having CGP as a partner and potential suitor may very well bring Merck to the table.
Market Data 
Markets 
AI
